 |
인쇄하기
취소
|
Can Boehringer Ingelheim’s Pradaxa be viable in Korean market?
The Korea Food and Drug Administration (FDA) has recently approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
As demonstrated in the previous clinical trials, Pradaxa 150mg taken twice daily has been shown to significantly reduce stroke and systemic embolism by 35 percent beyond the reduction ...
As demonstrated in the previous clinical trials, Pradaxa 150mg taken twice daily has been shown to significantly reduce stroke and systemic embolism by 35 percent beyond the reduction ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.